KLF transcription factor 1
Senast uppdaterad 4 mars 2025
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ljudversion
- Lägg till i föredragna källor på Google
The KLF1 gene provides instructions for making a protein that acts as a transcription factor, which means it attaches (binds) to specific regions of DNA and helps control the activity of particular genes. Specifically, the KLF1 protein helps control the activity of genes that are involved in the differentiation of red blood cells by regulating the final stages of red blood cell development (erythropoiesis).
Normal function
The KLF1 gene provides instructions for making a protein that acts as a transcription factor, which means it attaches (binds) to specific regions of DNA and helps control the activity of particular genes. Specifically, the KLF1 protein helps control the activity of genes that are involved in the differentiation of red blood cells by regulating the final stages of red blood cell development (erythropoiesis).
The KLF1 protein plays an important role in the production of hemoglobin, which is the protein in red blood cells that carries oxygen to cells and tissues throughout the body. During development, the KLF1 protein regulates the switch from the production of fetal hemoglobin, which is prevalent during embryonic development and early infancy, to the adult form of hemoglobin, which is produced throughout life.
Conditions referring to this gene or chromosome
Other names
EKLF
Erythroid krueppel-like transcription factor
Related patient information and medicines
Patient information leaflet
Akut lymfatisk leukemi
This is done in a similar way to a lumbar puncture (described above) and is called an intrathecal injection. In some cases, radiotherapy to the brain is also used. Stem cell transplantation (SCT) SCT - sometimes called bone marrow transplantation - may be performed. It may be used for cases where the leukaemia has come back (recurred) following.
Patient information leaflet
Hemofili
Hemofili is a rare bleeding disorder that affects your ability to make a clot. The blood contains substances called clotting factors that work with platelets to form a clot. When you injure yourself the clot stops you bleeding. Haemophilia is a condition where there is a deficiency of clotting factors, so people with this condition usually have.
Patient information leaflet
Typ 2-diabetesbehandling
If any of the above risk factors apply to you: If you are not currently on glucose-lowering treatment, your doctor will usually recommend you start taking metformin first. As soon as you are settled on metfor... GLP-1 (glucagon-like peptide-1) mimetics - exenatide, dulaglutide, liraglutide, lixisenatide and semaglutide Exenatide , dulaglutide,.
Patient information leaflet
Blodproppstester
Blodproppstester are used to diagnose and assess bleeding problems and to monitor people who take warfarin or other anticoagulant medicines. You may be advised to have blood clotting tests: If you have a suspected bleeding disorder. These chemicals then react with other chemicals and proteins in th... There are 13 known clotting factors which.
Patient information leaflet
Kan jag ta Apixaban och Rybelsus tillsammans?
These two medicines work in different ways and do not typically interfere with how the other is absorbed, broken down, or removed from the body. Why this happens Apixaban is an anticoagulant (blood thinner) that works by blocking a clotting factor called Factor Xa. Rybelsus is a GLP-1 receptor agonist used for type 2 diabetes that mimics a natural.
Patient information leaflet
Insulin
Insulin is a hormone made naturally in the body by the pancreas. This hormone controls the level of sugar (glucose) in the blood. People who have type 1 diabetes need to have regular insulin injections. In type 1 diabetes, the body stops making insulin and the blood sugar level goes very high. Some people who have type 2 diabetes may also need to.
Vidare läsning och referenser
- KLF transcription factor 1; MedlinePlus, National Library of Medicine.
- Bieker JJ, Philipsen S. Erythroid Kruppel-Like Factor (KLF1): A Surprisingly Versatile Regulator of Erythroid Differentiation. Adv Exp Med Biol. 2024;1459:217-242. doi: 10.1007/978-3-031-62731-6_10.
- Iolascon A, Andolfo I, Russo R. Congenital dyserythropoietic anemias. Blood. 2020 Sep 10;136(11):1274-1283. doi: 10.1182/blood.2019000948.
- Russo R, Iolascon A, Andolfo I, Marra R, Rosato BE. Updates on clinical and laboratory aspects of hereditary dyserythropoietic anemias. Int J Lab Hematol. 2024 Aug;46(4):595-605. doi: 10.1111/ijlh.14307. Epub 2024 May 15.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
4 mars 2025 | Senaste versionen
1 Mar 2025 | Ursprungligen publicerad
Delta i konversationen
Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.
Fråga, dela, anslut.
Bläddra i diskussioner, ställ frågor och dela erfarenheter inom hundratals hälsorelaterade ämnen.
Anmäl dig till Patientens nyhetsbrev
Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.